Figure 11 — Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis

Research Paper|Volume 15, Issue 16|pp. 8325–8344

Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis

Back to articleFigure 11(11 of 12)

100%

Figure 11.Drug sensitivity analysis. (A) BC patients with a high-risk score had a higher IC₅₀ value of eight therapeutic drugs compared with patients with a low-risk score. (B) BC patients with a high-risk score had a lower IC₅₀ value of many therapeutic drugs compared with patients with a low-risk score.